Canaccord Genuity Downgrades Neoleukin Therapeutics (NLTX) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Stifel Downgrades Neoleukin Therapeutics (NLTX) to Hold
November 15, 2022 4:58 AM ESTStifel analyst Benjamin Burnett downgraded Neoleukin Therapeutics (NASDAQ: NLTX) from Buy to Hold with a price target of $0.90 (from $14.00).
The analyst comments "We are downgrading shares to Hold following managements decision to discontinue development of lead asset NL-201 (next-gen IL-2 analogue). Management... More
